Amgen Continues to Grow Monoclonal Antibody Arsenal with Kirin’s KHK4083

By Debadrita Paul

Pharma Deals Review: Vol 2021 Issue 6 (Table of Contents)

Published: 25 Jun-2021

DOI: 10.3833/pdr.v2021.i6.2615     ISSN: 1756-7874

Section: Research & Development



In a bid to bolster its inflammatory disease portfolio, Amgen has agreed to partner with Kyowa Kirin to develop and commercialise the latter’s Phase III-ready asset, KHK4083...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details